Needham & Company Starts Vascular Solutions (VASC) at Buy

October 6, 2016 6:24 AM EDT
Get Alerts VASC Hot Sheet
Price: $55.90 --0%

Rating Summary:
    1 Buy, 5 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 7 | Down: 8 | New: 1
Trade VASC Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Needham & Company initiates coverage on Vascular Solutions (NASDAQ: VASC) with a Buy rating and a price target of $58.00.

Analyst Mike Matson commented, "VASC has a demonstrated ability to find and exploit attractive niches in interventional cardiology. A number of VASC's products are used for radial access and complex PCIs, which are both seeing rapid growth. VASC is developing RePlas freeze-dried plasma which we think could be a $100M+ product, and we believe VASC should be able to continue to drive significant operating leverage. While shares may look expensive, our scenario analysis suggest that they don't fully capture the potential value of RePlas, and we initiate coverage at Buy."

For an analyst ratings summary and ratings history on Vascular Solutions click here. For more ratings news on Vascular Solutions click here.

Shares of Vascular Solutions closed at $47.11 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage

Related Entities

Needham & Company

Add Your Comment